The European LeukemiaNet 2022 guidelines also classify additional conditions as adverse-risk disease in acute myeloid leukemia (AML), including mutations in myelodysplastic syndrome-related genes (ASXL1, RUNX1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2), and the cytogenetic fusion t(8;16) (KAT6A::CREBBP). Here, U2AF1 is linked to acute myeloid leukemia.